PubMed Health⌕ Search

Biomedical subjects

David Deng

Publications and source records attributed to David Deng.

2 recordsLinked to original sources

Identification of endothelial cell genes by combined database mining and microarray analysis.

Vascular endothelial cells maintain the interface between the systemic circulation and soft tissues and mediate critical processes such as inflammation in a vascular bed-selective fashion. To expand our understanding of the genetic pathways that underlie these specific functions, we have focused on the identification of novel genes that are differentially expressed in all endothelial cells, as well as restricted groups of this cell type. Virtual subtraction was conducted employing gene expression data deposited in public databases and 384 genes identified. These genes were spotted on custom microarrays, along with 288 genes identified through subtraction cloning from TGF-beta-stimulated endothelial cells. Arrays were evaluated with RNA samples representing endothelial cells cultured from four vascular sources and five non-endothelial cell types. These studies identified 64 pan-endothelial markers that were differentially expressed with at least a threefold difference (range 3- to 55-fold). In addition, differences in gene expression profiles among endothelial cells from different vascular beds were identified. Validation of these findings was performed by RNA blot expression studies, and a number of the novel genes were shown to be expressed under angiogenic conditions in the developing mouse embryo. The combined tools of database mining and transcriptional profiling thus provide expanded knowledge of endothelial cell gene expression and endothelial cell biology.

Adult↗

DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer.

PURPOSE: We hypothesized that DNA methylation regulates the differential expression of Y chromosome specific genes in prostate cancer. To test this hypothesis we analyzed the expression of Y chromosome specific genes in 5-aza-2'-deoxycytidine (5-azaC) treated and untreated prostate cancer cell lines. MATERIALS AND METHODS: To test this hypothesis Y chromosome specific genes were analyzed in prostate cancer cells treated with the demethylation agent 5-azaC. Total RNA was extracted and reverse transcribed, and polymerase chain reaction was performed using gene specific primers. These primers were designed based on the sequence available in the public genome data bank. The 10 Y chromosome specific genes DAZ, CDY, SRY, RBMY1A, RBMY1H, RBMII, BPY1, BPY2, PRY and TSPY were analyzed in the PC3, ND1, DU145, LNCaP, TSUPr1 and DUPro prostate cancer cell lines by reverse transcriptase-polymerase chain reaction. Normal testis RNA was used as a positive control. RESULTS: Of the 10 Y chromosome specific genes DAZ gene expression was lacking in all prostate cancer cell lines but after demethylation treatment with 5-azaC DAZ expression was restored. The SRY gene was also lacking in all prostate cancer cell lines except LNCaP. After demethylation SRY gene expression was restored in PC3, ND-1, DU-145, TSUPr1 and DUPro. There was no expression of the CDY and BPY2 genes before and after 5-azaC treatment in all prostate cancer cell lines. Expression of the RBMY1A, RBMY1H and RBMII genes was lacking in all prostate cancer cell lines but after demethylation the expression of all 3 was restored in the ND1, DU-145 and LNCaP cell lines. The BPY1 gene was only expressed in LNCaP cells but after treatment with 5-azaC all other cell lines, namely PC3, ND1, DU145, LNCaP and DUPro, restored BPY gene expression. PRY gene expression was lacking in all prostate cancer cell lines but after demethylation only LNCaP restored expression of this gene. TSPY was expressed only in LNCaP but after demethylation ND-1 cells restored expression of the TSPY gene. CONCLUSIONS: To our knowledge we report the first study showing that expression of the Y chromosome specific genes DAZ, SRY, RBMY1A, RBMY1H, RBMII, BPY1, PRY and TSPY is regulated by DNA methylation in prostate cancer.

Azacitidine↗